Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy?
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy?
Authors
Keywords
-
Journal
Nature Reviews Clinical Oncology
Volume 9, Issue 9, Pages 529-541
Publisher
Springer Nature
Online
2012-07-24
DOI
10.1038/nrclinonc.2012.121
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- p21-activated kinase 1: PAK’ed with potential
- (2015) Christy Ong et al. Oncotarget
- CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients
- (2012) James M. Rae et al. JNCI-Journal of the National Cancer Institute
- CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial
- (2012) Meredith M. Regan et al. JNCI-Journal of the National Cancer Institute
- Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial
- (2011) G. Viale et al. ANNALS OF ONCOLOGY
- Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review
- (2011) Elisabeth Luporsi et al. BREAST CANCER RESEARCH AND TREATMENT
- Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole – of clinical importance?
- (2011) J Geisler BRITISH JOURNAL OF CANCER
- Abstract 2: Naked CanScript, an 18-base pair sequence, has tumor cell-specific promoter activity in vivo: Implications for targeted gene therapy
- (2011) Janet A. Sawicki et al. CANCER RESEARCH
- Adjuvant Sequencing of Tamoxifen and Anastrozole Is Superior to Tamoxifen Alone in Postmenopausal Women with Low Proliferating Breast Cancer
- (2011) Z. Bago-Horvath et al. CLINICAL CANCER RESEARCH
- Tamoxifen Metabolite Concentrations, CYP2D6 Genotype, and Breast Cancer Outcomes
- (2011) L Madlensky et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Estrogen Receptor (ESR1) mRNA Expression and Benefit From Tamoxifen in the Treatment and Prevention of Estrogen Receptor–Positive Breast Cancer
- (2011) Chungyeul Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- Prevention and treatment of bone metastases
- (2011) Robert E. Coleman Nature Reviews Clinical Oncology
- Adjuvant Trastuzumab in HER2-Positive Breast Cancer
- (2011) Dennis Slamon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Predictive algorithms for adjuvant therapy: TransATAC
- (2011) Mitch Dowsett et al. STEROIDS
- A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole
- (2010) Zaida Garcia-Casado et al. BMC CANCER
- Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-analysis
- (2010) Bostjan Seruga et al. BREAST CANCER RESEARCH AND TREATMENT
- Phosphorylated S6K1 is a possible marker for endocrine therapy resistance in hormone receptor-positive breast cancer
- (2010) Eun-Kyu Kim et al. BREAST CANCER RESEARCH AND TREATMENT
- PKA-induced phosphorylation of ERα at serine 305 and high PAK1 levels is associated with sensitivity to tamoxifen in ER-positive breast cancer
- (2010) Marleen Kok et al. BREAST CANCER RESEARCH AND TREATMENT
- Functional Genetic Polymorphisms in the Aromatase Gene CYP19 Vary the Response of Breast Cancer Patients to Neoadjuvant Therapy with Aromatase Inhibitors
- (2010) L. Wang et al. CANCER RESEARCH
- FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer
- (2010) N. Turner et al. CANCER RESEARCH
- Targeting Endocrine Resistance: Is There a Role for mTOR Inhibition?
- (2010) Amna Sheri et al. Clinical Breast Cancer
- Estrogen Receptor- Phosphorylation at Serine 305, Nuclear p21-Activated Kinase 1 Expression, and Response to Tamoxifen in Postmenopausal Breast Cancer
- (2010) J. Bostner et al. CLINICAL CANCER RESEARCH
- New Strategies in Estrogen Receptor-Positive Breast Cancer
- (2010) S. R. D. Johnston CLINICAL CANCER RESEARCH
- Low-Molecular-Weight Cyclin E Can Bypass Letrozole-Induced G1 Arrest in Human Breast Cancer Cells and Tumors
- (2010) S. Akli et al. CLINICAL CANCER RESEARCH
- 17ß-Hydroxysteroid dehydrogenase type 1 as predictor of tamoxifen response in premenopausal breast cancer
- (2010) Ann-Christine Källström et al. EUROPEAN JOURNAL OF CANCER
- p27Kip1 is a predictive factor for tamoxifen treatment response but not a prognostic marker in premenopausal breast cancer patients
- (2010) Maria Stendahl et al. INTERNATIONAL JOURNAL OF CANCER
- Differential Requirements of Hsp90 and DNA for the Formation of Estrogen Receptor Homodimers and Heterodimers
- (2010) Emily Powell et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Genomic Index of Sensitivity to Endocrine Therapy for Breast Cancer
- (2010) W. Fraser Symmans et al. JOURNAL OF CLINICAL ONCOLOGY
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
- (2010) M. Elizabeth H. Hammond et al. JOURNAL OF CLINICAL ONCOLOGY
- Management of breast cancer with targeted agents: importance of heterogenicity
- (2010) Serena Di Cosimo et al. Nature Reviews Clinical Oncology
- Biomarkers and surrogate end points—the challenge of statistical validation
- (2010) Marc Buyse et al. Nature Reviews Clinical Oncology
- Expression of Estrogen Receptor Beta and Phosphorylation of Estrogen Receptor Alpha Serine 167 Correlate with Progression-Free Survival in Patients with Metastatic Breast Cancer Treated with Aromatase Inhibitors
- (2010) Kazuyoshi Motomura et al. ONCOLOGY
- PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer
- (2010) S. Loi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer
- (2009) Katrine L. Henriksen et al. ACTA ONCOLOGICA
- AIB1 is a predictive factor for tamoxifen response in premenopausal women
- (2009) S. Alkner et al. ANNALS OF ONCOLOGY
- Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer
- (2009) Matthew J. Ellis et al. BREAST CANCER RESEARCH AND TREATMENT
- The Tamoxifen Metabolite, Endoxifen, Is a Potent Antiestrogen that Targets Estrogen Receptor for Degradation in Breast Cancer Cells
- (2009) X. Wu et al. CANCER RESEARCH
- Predictors of response to exemestane as primary endocrine therapy in estrogen receptor-positive breast cancer
- (2009) Hiroko Yamashita et al. CANCER SCIENCE
- Ratio of 17HSD1 to 17HSD2 Protein Expression Predicts the Outcome of Tamoxifen Treatment in Postmenopausal Breast Cancer Patients
- (2009) A. Jansson et al. CLINICAL CANCER RESEARCH
- Coassociation of Estrogen Receptor and p160 Proteins Predicts Resistance to Endocrine Treatment; SRC-1 is an Independent Predictor of Breast Cancer Recurrence
- (2009) A. M. Redmond et al. CLINICAL CANCER RESEARCH
- Ras/Raf-1/MAPK Pathway Mediates Response to Tamoxifen but not Chemotherapy in Breast Cancer Patients
- (2009) L. M. McGlynn et al. CLINICAL CANCER RESEARCH
- Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer
- (2009) Stephen Johnston et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study
- (2009) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer
- (2009) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers
- (2009) R. M. Simon et al. JNCI-Journal of the National Cancer Institute
- Estrogen Receptor-α Phosphorylation at Serine-118 and Tamoxifen Response in Breast Cancer
- (2009) Marleen Kok et al. JNCI-Journal of the National Cancer Institute
- Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
- (2009) Maggie C. U. Cheang et al. JNCI-Journal of the National Cancer Institute
- Estrogen receptor beta in breast cancer—Diagnostic and therapeutic implications
- (2009) Johan Hartman et al. STEROIDS
- Plasma membrane estrogen receptors
- (2009) Ellis R. Levin TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Phosphorylated Insulin-Like Growth Factor-I/Insulin Receptor Is Present in All Breast Cancer Subtypes and Is Related to Poor Survival
- (2008) J. H. Law et al. CANCER RESEARCH
- Down-Regulation of Phosphatidylinositol 3'-Kinase/AKT/Molecular Target of Rapamycin Metabolic Pathway by Primary Letrozole-Based Therapy in Human Breast Cancer
- (2008) D. Generali et al. CLINICAL CANCER RESEARCH
- A Single-Nucleotide Polymorphism in the Aromatase Gene Is Associated with the Efficacy of the Aromatase Inhibitor Letrozole in Advanced Breast Carcinoma
- (2008) R. Colomer et al. CLINICAL CANCER RESEARCH
- Cyclin D1 Expression in Breast Cancer Patients Receiving Adjuvant Tamoxifen-Based Therapy
- (2008) M. Rudas et al. CLINICAL CANCER RESEARCH
- Clinical Implications of CYP2D6 Genotyping in Tamoxifen Treatment for Breast Cancer
- (2008) V. O. Dezentje et al. CLINICAL CANCER RESEARCH
- Low phosphorylation of estrogen receptor (ER ) serine 118 and high phosphorylation of ER serine 167 improve survival in ER-positive breast cancer
- (2008) H. Yamashita et al. ENDOCRINE-RELATED CANCER
- Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole
- (2008) Giuseppe Viale et al. JOURNAL OF CLINICAL ONCOLOGY
- Crosstalk Between IGF1R and Estrogen Receptor Signaling in Breast Cancer
- (2008) Dedra H. Fagan et al. JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA
- Non-classical genomic estrogen receptor (ER)/specificity protein and ER/activating protein-1 signaling pathways
- (2008) Stephen Safe et al. JOURNAL OF MOLECULAR ENDOCRINOLOGY
- Phosphorylation of the oestrogen receptor α at serine 305 and prediction of tamoxifen resistance in breast cancer
- (2008) C Holm et al. JOURNAL OF PATHOLOGY
- Outcome Prediction for Estrogen Receptor-Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics
- (2008) M. J. Ellis et al. JNCI-Journal of the National Cancer Institute
- Letting the Genome out of the Bottle — Will We Get Our Wish?
- (2008) David J. Hunter et al. NEW ENGLAND JOURNAL OF MEDICINE
- Induction of ErbB-3 Expression by α6β4 Integrin Contributes to Tamoxifen Resistance in ERβ1-Negative Breast Carcinomas
- (2008) Valentina Folgiero et al. PLoS One
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started